LEVIN JEREMY M 4

What Happened
Jeremy M. Levin, a director of Ovid Therapeutics, received a derivative award on 2026-02-26 covering 957,000 shares (reported acquisition price $0.00) — recorded on a Form 4 filed 2026-03-02. This was an equity award (stock option/derivative), not an open-market purchase or sale, so it does not represent immediate common-share ownership or a cash transaction.

Key Details

• Transaction date: 2026-02-26; Form 4 filed: 2026-03-02 (filing appears timely).
• Security: Derivative (stock option/award) covering 957,000 shares; acquisition price shown as $0.00 on the Form 4.
• Shares owned after transaction: not specified in the filing.
• Footnote: the option vests in 48 equal monthly installments beginning March 20, 2026, subject to Levin’s continued service.
• No 10b5-1 plan, tax-withholding sale, or late-filing flag noted in this filing.

Context
This was an option/award grant, meaning Levin must wait for vesting and then (if applicable) exercise the option to obtain common shares. The Form 4 shows a $0.00 acquisition amount for reporting but does not by itself disclose any exercise price or tax treatment; check the company’s related 8-K, proxy, or equity plan filings for exercise price and other terms if you need the full economic details.